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Abstract In the present study, we examined the regulation of 
tetranectin gene expression using a human osteoblastic ell line, 
SV-HFO, that undergoes mineralization upon treatment with 
dexamethasone. We found that the expression of tetranectin and 
alkaline phosphatase mRNA was induced by dexamethasone 
treatment as evidenced by Northern blotting. When transforming 
growth factor-/] 1 (TGF-/] 0 was added together with dexa- 
methasone to the SV-HFO cell cultures, the mineralization 
process was markedly suppressed and the expression of tetra 
nectin and alkaline phosphatase was downregulated in a dose- 
dependent manner. These results demonstrate that the expression 
of tetranectin in these osteoblastic ells is regulated by dexa- 
methasone and TGF-/] 1 and that tetranectin expression is tightly 
linked to the process of mineralization. 
of both alkaline phosphatase and osteocalcin [24]. More re- 
cently, we have shown that the cells undergo mineralization 
upon treatment with glucocorticoids [25]. In the present study, 
we used this human osteoblastic n vitro model system to begin 
analysing the regulation of tetranectin gene expression during 
mineralization. Tetranectin is a protein originally isolated from 
plasma [26] that was found to be expressed in bone at a time 
and space coincident with mineralization in vivo and in vitro 
[27]. We report that dexamethasone treatment induced the ex- 
pression of tetranectin mRNA and that TGF-fl~ inhibited min- 
eralization and the induction of tetranectin mRNA.  
2. Materials and methods 
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1. Introduction 
Transforming rowth factor fll (TGF-flj) is a multifunctional 
compound that affects the proliferation, differentiation and 
gene expression pattern of several cell types, including osteo- 
blasts [1-3]. Bone is an abundant source of TGFofll [1,2] and 
in vivo studies have shown that TGF-fll is a local regulator of 
bone formation. In osteoblast cell culture systems, TGF-fl l  
regulates the mineralization process and the expression of os- 
teoblastic markers, including alkaline phosphatase, c~1 (I) pro- 
collagen, osteopontin, osteonectin and osteocalcin [4-22]. 
We have recently established a human osteoblastic cell line, 
SV-HFO, by immortalizing normal human fetal calvaria os- 
teoblasts with simian virus 40 (SV-40) [23]. The cells had mor- 
phological and ultrastructural features characteristic of osteo- 
blasts and produced low levels of osteoblastic markers like 
alkaline phosphatase and osteocalcin. The osteoblastic SV- 
HFO cells responded to osteotropic factors 1 ~,25-dihydroxyvi- 
tamin D3, retinoic acid and TGF-flj [24]. The direct effect of 
TGF-fll on SV-HFO cells included a reduction of the amount 
*Corresponding author. Laboratory of Molecular Pathology, 
University Insitute of Pathological Anatomy, Frederik V's vej 11, 
2100 Copenhagen O, Denmark. Fax: (45) (35) 32 60 81. 
**To whom reprint requests hould be addressed. Department of 
Pathology, Sapporo Medical University School of Medicine, 
S.I., W.17, Chuo-ku, Sapporo 060, Japan. Fax: (81) (11) 613 5665. 
2.1. Cell culture 
The human osteoblastic SV-HFO cell line was established, cloned 
and maintained as previously described at 37°C in a humidified atmos- 
phere of 95% air and 5% CO2 [23]. The cells at passage 14 were seeded 
at a cell density of 1 x l0 4 cells/cm 2on 35- or 100-mm culture dishes 
(Corning Glass Works, Corning, NY) in c~-minimal essential medium 
(c~-MEM; GIBCO Laboratories, Grand Island, NY) supplemented 
with 10% fetal bovine serum (FBS; HR Bioscience, Lenexa, KS), 10 
mM fl-glycerophosphate (fl-GP; Sigma, St Louis, MO), 100 U/ml pen- 
icillin and 100/lg/ml streptomycin (Immuno Biological Laboratories, 
Fujioka, Japan) and 20 mM N-2-hydroxyethylpiperazine-N'-ethane 
sulfonic acid (Hepes; Sigma). After 6 days of culture, the cells had 
reached confluence and dexamethasone (10-6 M; Orgadrone, Sankyo, 
Tokyo, Japan) was added to the cultures either alone or together with 
TGF-fll (human platelet-derived TGF-fl6 Sigma) at various concentra- 
tions (0.5 or 5 ng/ml). The cultures were maintained for another 7 or 
21 days and then examined by von Kossa staining for minerals, calcium 
(Ca) and phosphate (P) measurements and used for the isolation of total 
RNA. The complete culture medium was renewed every 2-3 days. 
2.2. Histochemical detection of minerals 
The cells were rinsed with PBS, fixed in 20% formalin overnight and 
stained by the von Kossa technique for the detection of minerals [28]. 
2.3. Biochemical detection of minerals 
The cells were rinsed with Hank's balanced salt solution (pH 7.4) and 
minerals deposited in the extracellular matrix were extracted with 0.8 
ml of 5% perchloric acid at 4°C. The amount of Ca was measured 
spectrophotometrically by the o-cresolphtain Complexone method [29] 
and that of P was determined by the eolorimetric method of Chen et 
al. [30]. 
2.4. RNA isolation and Northern blot analys& 
Total RNA was isolated from cultures using the single-step guanidine 
thiocyanate-phenol-chloroform extraction method [31] with modifica- 
tions as described [32]. For electrophoresis, 10¢tg of total RNA was 
separated on a 1% agarose gel containing 0.5 ,ug/ml ethidium bromide. 
The RNA was capillary blotted onto nylon membranes (Hybond-N; 
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Amersham, Amersham, UK) in 20 × saline sodium citrate (SSC) and 
cross-linked with UV light. Human cDNA probes were as follows: ~1 
(I) procoUagen [33] kindly provided by Dr. Yasuko Koshihara (Depart- 
ment of Biosignal Research, Tokyo Metropolitan I stitute of Gerontol- 
ogy); osteocalcin [34] was generously provided by Dr. Shintaro Nomura 
(Department of Pathology, Osaka University Medical School); alkaline 
phosphatase and TGF-fll from the American Type Culture Collection; 
and human tetranectin [35]. The probes were labeled with 32p using 
multiprime DNA-labeling system kit (Amersham). The blots were pre- 
hybridized in a solution containing 50% formamide, 0.9 M NaC1, 0.1 
M NaPO 4 (pH 7.4), 0.1% sodium dodecyl sulfate (SDS), 10 pg/ml 
herring sperm DNA and 5 × Denhardt's solution at 42°C for 4 h and 
then hybridized overnight at 4°C in the same solution containing the 
32p-labeled probes. The membranes were exposed to Kodak Diagnostic 
film (Eastman Kodak, Rochester, NY) and an imaging plate and analy- 
sed using a Bio Imagining Analyser BAS 2000 (Fujix, Tokyo, Japan). 
2.5. Statistical analysis 
The data was statistically analysed using an unpaired, double-sided 
t test. All data were represented as mean values of four different dishes. 
3. Results 
The human osteoblastic cell line SV-HFO undergoes miner- 
alization in vitro upon treatment with the glucocorticoid, ex- 
amethasone (10 -6 M) as demonstrated histochemically b von 
A 
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Fig. 1. Von Kossa staining for minerals of human osteoblastic SV-HFO 
cells cultured for 21 days without (A) or with dexamethasone (10 -6 M) 
(B) or in the presence ofboth dexamethasone a d TGF-fll (5 ng/ml) (C). 
Magnification × 27. 
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Fig. 2. Measurement of the amount in mM of calcium (Ca) and phos- 
phate (P) in human osteoblastic SV-HFO cells cultured for 21 days 
without any treatment (1), in the presence of 10 -6 M dexamethasone 
(2) or in the presence of 10 -6 M dexamethasone combined with 0.5 (3) 
or 5 ng/ml (4) of TGF-fll. The mean + S.D. values of four different 
dishes with duplicate determinations are shown. (a) denotes that the 
values are significantly different from the values of cells cultured with 
dexamethasone alone; P < 0.001. 
Kossa staining for minerals (Fig. 1A,B [25]). When confluent 
SV-HFO cells were grown for 21 days in the presence of dexa- 
methasone and TGF-flx (5 ng/ml), a strong inhibition of miner- 
alization was observed (Fig. 1C). This inhibitory effect of TGF- 
fll was quantitated by measuring the amount of deposited cal- 
cium (Ca) and phosphate (P) and was found to be dose-depend- 
ent. As demonstrated in Fig. 2, the addition of 0.5 ng/ml TGF- 
fit to the cultures reduced the amount of Ca and P by ~30% 
(P < 0.001) while 5 ng/ml of TGF-fll resulted in an almost 
complete inhibition (P < 0.001) of Ca and P deposition. 
The influence of dexamethasone and TGF-fl~ on the expres- 
sion of a series of bone marker proteins by the osteoblastic cells 
SV-HFO was examined by Northern blotting (Fig. 3A,B). The 
level of expression of alkaline phosphatase mRNA induced by 
dexamethasone tr atment was downregulated by TGF-flj at 
concentrations of both 0.5 and 5 ng/ml (Fig. 3A) while the level 
of expression of 0q (I) procollagen, osteocalcin and endogene- 
ous TGF-fll in dexamethasone-treated cells appeared unaf- 
fected by TGF-fll (Fig. 3A). We then investigated the expres- 
sion of tetranectin, a protein recently found to play a potential 
role in mineralization [27]. The expression of tetranectin 
mRNA was dramatically induced by the addition of dexam- 
ethasone (10 -6 M) to the cell cultures (Fig. 3B, cf. lanes 1 with 
2 and lanes 5 with 6). In cultures treated with both dexam- 
ethasone and 0.5 ng/ml TGF-fll for 7 days, tetranectin mRNA 
was present (Fig. 3B, lane 3) while, after 21 days of exposure 
to both compounds, no tetranectin mRNA could be detected 
(Fig. 3B, lane 6). When higher doses of TGF-fll (5 ng/ml) were 
applied, the induction of tetranectin mRNA was completely 
abolished at both time points (Fig. 3B, lanes 4 and 8), showing 
that the inhibitory effect of TGF-fll on the dexamethasone- 
induced expression of tetranectin mRNA was time- and dose- 
dependent. 
4. Discussion 
In this study, we have shown that the expression of tetra- 
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Fig. 3. (A, left) Northern blot analysis of mRNA for alkaline phosphatase (ALP), ~ (I) procollagen (cq(I)Col), osteocalcin (OC) and TGF-fll from 
human osteoblastic SV-HFO cells. Lane 1, no treatment; lane 2, 10 -6 M dexamethasone; lane 3, 10 -6 M dexamethasone and 0.5 ng/ml TGF-fl~; and 
lane 4, 10 -6 M and 5 ng/ml TGF-flv (B, right) Northern blot analysis of tetranectin mRNA (TET) isolated from human osteoblastic SV-HFO cells 
cultured for 7 days (lanes 14) and 21 days (lanes 5-8) under the following conditions: lanes 1 and 5, no treatment; lanes 2 and 6, 10 -6 M 
dexamethasone; lanes 3 and 7, 10 -6 M dexamethasone and 0.5 ng/ml TGF-fll; and lanes 4 and 8, 10 -6 M dexamethasone and 5 ng/ml TGF-flv The 
sizes of the hybridizing mRNAs are indicated in kb. Lower panels, the ethidium-bromide stained RNA samples before transfer, ribosomal markers 
18S and 28S are indicated. 
nectin mRNA is upregulated uring the dexamethasone-in- 
duced mineralization of the human osteoblastic cell line SV- 
HFO in vitro. This inductive ffect of dexamethasone on tetra- 
nectin expression was inhibited by TGF-fll in a dose-dependent 
manner. The changes in tetranectin mRNA expression were 
paralleled by changes in alkaline phosphatase gene expression 
and the mineralization process. Our results provide new insight 
into the possible regulation of tetranectin mRNA expression 
during mineralization i  osteogenesis and show that tetranectin 
expression is tightly correlated to the mineralization process. 
Understanding the modulation of the osteoblastic phenotype 
is of interest in light of the its important role in, for example, 
the formation of new bone during fracture healing as well as 
in the maintenance ofexisting bone to prevent osteoporosis [2]. 
Furthermore, carcinoma cells have an intriguing effect on the 
bone metabolism, including the formation of osteolytic and 
osteosclerotic metastases [36]. It is becoming clear that the 
TGF-fl supergene family plays an instrumental role for the 
osteoblastic cell lineage to display its full catalogue of pheno- 
typic characteristics during osteogenesis. In various experimen- 
tal systems for studying bone formation, contradictory esults 
have been obtained on whether TGF-fll enhances or inhibits 
bone matrix formation, mineralization and the expression of 
bone marker proteins [4-22]. This has in part been explained 
by differences in the source and type of cells, stage of osteoblas- 
tic maturation, culture conditions and presence of other cyto- 
kines and their receptors. The cell system employed in the 
present study consists of an SV-40 immortalized human osteo- 
blastic cell line (SV-HFO) [23] that undergo differentiation as 
evidenced by mineralization, upon treatment with dexa- 
methasone [25]. Our results demonstrating that TGF-fl~ inhibits 
alkaline phosphatase expression and mineralization are consis- 
tent with several previous tudies howing that TGF-fll appears 
to be an inhibitor of bone nodule formation and mineralization 
in osteoblast cultures [8-10,13,37]. A number of in vivo models 
have been established and it has been repeatedly shown that 
TGF-fl injections timulated bone formation [4-7]. However, 
endochondral ossification did not occur until after TGF-fl in- 
jection had ceased [5]. Based on all these in vitro and in vivo 
studies, several authors suggested that, while TGF-fll initiates 
the proliferation, differentiation and extracellular matrix syn- 
thesis of bone cells, TGF-fll may be less involved in or actually 
inhibit the later phases of osteogenesis, i.e. mineralization 
[17,20,21]. The biological responses to TGF-fl may be mediated 
by the retinoblastoma gene product [38], which binds to the 
SV-40 T antigen, and therefore the effect of T antigen expres- 
sion by the SV-HFO cells on the TGF-fll signal transduction 
pathway will require further analysis. 
The inhibition of mineralization of dexamethasone-treated 
SV-HFO cells by TGF-fll was associated with a strong inhibi- 
tion of tetranectin gene expression as well as that of alkaline 
phosphatase. This demonstrates that tetranectin expression is
tightly linked to mineralization, consistent with previous tud- 
ies [27]. Although the exact biological function of tetranectin 
is unknown, it binds to the fourth kringle domain of plasmino- 
gen [25] and has a homology to C-type lectins which display 
calcium-dependent binding to carbohydrates [39,40]. The 
human and mouse cDNAs have been cloned [35,41,42] and the 
structure of the human tetranectin gene has been determined 
[43]. No information has yet been obtained on the regulation 
of the mouse or human tetranectin gene. The promoters of 
several of the bone-related genes contain an AP-l-binding site 
and for osteocalcin it has been demonstrated that this site may 
mediate the effect of TGF-fl~ by binding to the fos-jun complex 
[44]. Thus, it will be of interest to determine whether the tetra- 
nectin gene contains regulatory motifs similar to those found 
in other bone-related genes. Another aspect hat merits further 
exploration is to test the effect of TGF-fll on tetranectin gene 
expression i  other in vitro and in vivo bone model systems. In 
conclusion, our study provides the first evidence that the regu- 
lation of the tetranectin gene has important biological implica- 
tions. 
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